- Home
- OPT vs PCN Comparison
OPT vs PCN Comparison
Compare OPT & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PCN
- Stock Information
- Founded
- OPT 1984
- PCN 2001
- Country
- OPT Australia
- PCN United States
- Employees
- OPT N/A
- PCN N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PCN Investment Managers
- Sector
- OPT Health Care
- PCN Finance
- Exchange
- OPT Nasdaq
- PCN Nasdaq
- Market Cap
- OPT 767.9M
- PCN 728.5M
- IPO Year
- OPT 2020
- PCN N/A
- Fundamental
- Price
- OPT $3.60
- PCN $13.51
- Analyst Decision
- OPT Strong Buy
- PCN
- Analyst Count
- OPT 1
- PCN 0
- Target Price
- OPT $12.00
- PCN N/A
- AVG Volume (30 Days)
- OPT 9.2K
- PCN 218.7K
- Earning Date
- OPT 08-30-2024
- PCN 01-01-0001
- Dividend Yield
- OPT N/A
- PCN 9.73%
- EPS Growth
- OPT N/A
- PCN N/A
- EPS
- OPT N/A
- PCN N/A
- Revenue
- OPT $261,859.00
- PCN N/A
- Revenue This Year
- OPT N/A
- PCN N/A
- Revenue Next Year
- OPT $46,864.64
- PCN N/A
- P/E Ratio
- OPT N/A
- PCN N/A
- Revenue Growth
- OPT N/A
- PCN N/A
- 52 Week Low
- OPT $1.79
- PCN $10.70
- 52 Week High
- OPT $5.45
- PCN $14.48
- Technical
- Relative Strength Index (RSI)
- OPT 52.65
- PCN 33.94
- Support Level
- OPT $3.15
- PCN $13.18
- Resistance Level
- OPT $3.39
- PCN $14.16
- Average True Range (ATR)
- OPT 0.17
- PCN 0.16
- MACD
- OPT 0.05
- PCN -0.06
- Stochastic Oscillator
- OPT 72.31
- PCN 33.47
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income. The secondary investment objective of the fund is capital preservation and appreciation. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.